The Solute Carrier Superfamily as Therapeutic Targets in Pancreatic Ductal Adenocarcinoma
The study identifies four SLCs as therapeutic targets in PDAC, highlighting their crucial role in essential metabolic pathways. These findings lay the groundwork for developing next-generation metabolic anti-cancer treatment to improve survival for PDAC patients.
Authors
- Jaejeung Kim (ORCID: https://orcid.org/0000-0002-3714-0280)
- Hyuk Soo Eun (ORCID: https://orcid.org/0000-0003-0485-0072)
- Jong Seok Joo (ORCID: https://orcid.org/0000-0001-8286-0095)
- Y. Ko (ORCID: https://orcid.org/0009-0003-1404-0943)
- Woo Sun Rou (ORCID: https://orcid.org/0000-0003-1619-2660)
- Sang Yeon Cho
Institutions
- Chungnam National University (KR)
- Chungnam National University Hospital (KR)
Publication Details
- Journal
- Genes
- Published
- 2025-04-18
- DOI
- https://doi.org/10.3390/genes16040463
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09